^
    Back
    Association details:
    Biomarker:EML4-ALK fusion
    Cancer:Non Small Cell Lung Cancer
    Drug:Lorbrena (lorlatinib) (ALK inhibitor, ROS1 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China

    Excerpt:
    ...Evidence of histologically or cytologically confirmed diagnosis of locally advanced or metastatic ALK positive NSCLC where ALK status has been previously established by the Ventana ALK (D5F3) CDx Assay (Roche Diagnostics), the Vysis ALK Break Apart FISH Probe Kit (Abbott Molecular), or the EML4 ALK Fusion Gene Detection Kit (AmoyDx)....
    Trial ID:
    NCT03909971
    Evidence Level:
    Resistant: D – Preclinical
    New
    Source:
    Cancer Discov
    Title:

    Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer

    Excerpt:
    To model resistance to lorlatinib in vivo, we generated subcutaneous tumors from the sensitive EML4-ALK v1 cell line MGH006. Tumor-bearing mice were treated with lorlatinib by oral gavage, leading to tumor regression for more than 50 days, as previously reported (17). With continued lorlatinib treatment, three of six tumors showed regrowth consistent with the emergence of resistance.
    DOI:
    10.1158/2159-8290.CD-17-1256